KR102889909B1 - 연성 항콜린성 에스테르를 위한 방법 및 조성물 - Google Patents

연성 항콜린성 에스테르를 위한 방법 및 조성물

Info

Publication number
KR102889909B1
KR102889909B1 KR1020187009786A KR20187009786A KR102889909B1 KR 102889909 B1 KR102889909 B1 KR 102889909B1 KR 1020187009786 A KR1020187009786 A KR 1020187009786A KR 20187009786 A KR20187009786 A KR 20187009786A KR 102889909 B1 KR102889909 B1 KR 102889909B1
Authority
KR
South Korea
Prior art keywords
hydroxyacetoxy
cyclopentyl
phenyl
methylpyrrolidinium bromide
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020187009786A
Other languages
English (en)
Korean (ko)
Other versions
KR20180061220A (ko
Inventor
니콜라스 에스. 보더
Original Assignee
보도르 라보래토리즈, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 보도르 라보래토리즈, 인크. filed Critical 보도르 라보래토리즈, 인크.
Publication of KR20180061220A publication Critical patent/KR20180061220A/ko
Application granted granted Critical
Publication of KR102889909B1 publication Critical patent/KR102889909B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7007—Drug-containing films, membranes or sheets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12—Oxygen or sulfur atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Inorganic Chemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020187009786A 2015-09-11 2016-09-06 연성 항콜린성 에스테르를 위한 방법 및 조성물 Active KR102889909B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562217362P 2015-09-11 2015-09-11
US62/217,362 2015-09-11
PCT/US2016/050385 WO2017044412A1 (en) 2015-09-11 2016-09-06 Methods and compositions for soft anticholinergic esters

Publications (2)

Publication Number Publication Date
KR20180061220A KR20180061220A (ko) 2018-06-07
KR102889909B1 true KR102889909B1 (ko) 2025-11-24

Family

ID=58239861

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020187009786A Active KR102889909B1 (ko) 2015-09-11 2016-09-06 연성 항콜린성 에스테르를 위한 방법 및 조성물

Country Status (12)

Country Link
US (4) US11534422B2 (enExample)
EP (1) EP3347007B1 (enExample)
JP (4) JP7270958B2 (enExample)
KR (1) KR102889909B1 (enExample)
CN (4) CN118045082A (enExample)
AU (2) AU2016318595B2 (enExample)
ES (1) ES2942361T3 (enExample)
IL (1) IL257970B (enExample)
MX (1) MX388831B (enExample)
MY (1) MY197265A (enExample)
WO (1) WO2017044412A1 (enExample)
ZA (1) ZA201801685B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109044965A (zh) * 2018-10-17 2018-12-21 广州大光制药有限公司 格隆溴铵的眼用药物组合物及医药用途
US20230149349A1 (en) * 2020-03-03 2023-05-18 Kaken Pharmaceutical Co., Ltd. Medicament containing sofpironium bromide
CN118119392A (zh) 2021-11-01 2024-05-31 犹他大学研究基金会 用于治疗流涎的组合物和方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080102102A1 (en) 2005-01-19 2008-05-01 Neurohealing Pharmaceuticals, Inc. Methods And Compositions For Decreasing Saliva Production
US20140275204A1 (en) 2013-03-15 2014-09-18 Bodor Laboratories, Inc. Method of dosing and use of soft anticholinergic esters

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2879100A (en) * 1999-02-12 2000-08-29 Miles A. Libbey Iii Formulation and system for intra-oral delivery of pharmaceutical agents
WO2001008681A1 (en) 1999-08-02 2001-02-08 First Horizon Pharmaceutical Corporation Methods of administration of glycopyrrolate compositions
ATE529399T1 (de) 2005-11-10 2011-11-15 Nicholas S Bodor Sanfte anticholinerge ester
EP1957451B1 (en) 2005-11-10 2011-10-19 Nicholas S. Bodor Soft anticholinergic zwitterions
US8071693B2 (en) 2006-06-22 2011-12-06 Sabic Innovative Plastics Ip B.V. Polysiloxane/polyimide copolymers and blends thereof
US20080260823A1 (en) * 2007-04-20 2008-10-23 Sciele Pharma, Inc. Orally disintegrating tablet comprising glycopyrrolate for treating sialorrhea
JP2010530902A (ja) 2007-06-22 2010-09-16 サイエル ファーマ,インコーポレイティド 流涎症治療のためのグリコピロレートを含む経皮送達システム
US8628729B2 (en) 2008-03-27 2014-01-14 President And Fellows Of Harvard College Three-dimensional microfluidic devices

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080102102A1 (en) 2005-01-19 2008-05-01 Neurohealing Pharmaceuticals, Inc. Methods And Compositions For Decreasing Saliva Production
US20140275204A1 (en) 2013-03-15 2014-09-18 Bodor Laboratories, Inc. Method of dosing and use of soft anticholinergic esters

Also Published As

Publication number Publication date
US12458625B2 (en) 2025-11-04
MY197265A (en) 2023-06-08
WO2017044412A1 (en) 2017-03-16
HK1255558A1 (en) 2019-08-23
ES2942361T3 (es) 2023-05-31
JP2022132446A (ja) 2022-09-08
JP2018526420A (ja) 2018-09-13
KR20180061220A (ko) 2018-06-07
JP2021001238A (ja) 2021-01-07
CN118045082A (zh) 2024-05-17
AU2021204306A1 (en) 2021-07-22
US20240261262A1 (en) 2024-08-08
CN108348502A (zh) 2018-07-31
JP2023164671A (ja) 2023-11-10
EP3347007B1 (en) 2023-03-29
US11951093B2 (en) 2024-04-09
JP7270958B2 (ja) 2023-05-11
CN118021797A (zh) 2024-05-14
IL257970A (en) 2018-05-31
AU2016318595B2 (en) 2021-07-08
IL257970B (en) 2021-04-29
CN118021770A (zh) 2024-05-14
US20180250265A1 (en) 2018-09-06
JP7723417B2 (ja) 2025-08-14
US20220401410A1 (en) 2022-12-22
ZA201801685B (en) 2023-12-20
EP3347007A1 (en) 2018-07-18
EP3347007A4 (en) 2019-05-08
MX388831B (es) 2025-03-20
US11534422B2 (en) 2022-12-27
AU2021204306B2 (en) 2023-11-09
US20260108491A1 (en) 2026-04-23
AU2016318595A1 (en) 2018-04-26
CA2998357A1 (en) 2017-03-16
MX2018003002A (es) 2018-08-01

Similar Documents

Publication Publication Date Title
US12458625B2 (en) Methods and compositions for soft anticholinergic esters
JP5941558B2 (ja) シルデナフィルを有効成分として含有し、且つ、苦味の隠蔽された高含量速溶フィルム
EP2744572B1 (en) Abuse-resistant mucoadhesive devices for delivery of buprenorphine
EP4523752A2 (en) Film formulations containing dexmedetomidine and methods of producing them
JP2000063268A (ja) 口腔粘膜付着型徐放性錠剤及び歯周疾患治療剤
CA2998357C (en) Compositions comprising a soft anticholinergic ester
HK40110882A (en) Methods and compositions for soft anticholinergic esters
HK40110881A (en) Methods and compositions for soft anticholinergic esters
US20180235869A1 (en) Methods and compositions for soft anticholinergic zwitterions
HK40111398A (en) Methods and compositions for soft anticholinergic esters
JP2006070027A (ja) 口腔粘膜投与剤
HK1255558B (en) Methods and compositions for soft anticholinergic esters
KR101440808B1 (ko) 실데나필 또는 이의 약제학적으로 허용되는 염을 고함량으로 포함하는 속용필름
JP2001002590A (ja) 口腔粘膜付着型徐放性錠剤
HK40082930B (en) Transmucosal therapeutic system containing agomelatine
HK40082930A (en) Transmucosal therapeutic system containing agomelatine
HK1198958B (en) Abuse-resistant mucoadhesive devices for delivery of buprenorphine

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

F13 Ip right granted in full following pre-grant review

Free format text: ST27 STATUS EVENT CODE: A-3-4-F10-F13-REX-PX0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PX0701 Decision of registration after re-examination

St.27 status event code: A-3-4-F10-F13-rex-PX0701

F11 Ip right granted following substantive examination

Free format text: ST27 STATUS EVENT CODE: A-2-4-F10-F11-EXM-PR0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

U12 Designation fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U12-OTH-PR1002 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

Q13 Ip right document published

Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q13-NAP-PG1601 (AS PROVIDED BY THE NATIONAL OFFICE)